Perfil de la empresa · Healthcare

Bristol-Myers Squibb Company

BMY · EE. UU.
Bolsa
EE. UU.
País / Región
USA
Fecha de salida a bolsa
1 de enero de 1972
Empleados
32.500
Sitio web
www.bms.com
Precio actual
$54
En vivo · 18 de junio de 2026
Puntuación de crecimiento Baillie
43/100
Floja
Valor intrínseco · Rango en tres niveles Precio actual $54 En vivo · Dentro del rango de valor intrínseco razonable

Rango de valoración compuesto · conservador $45–$52 / razonable $52–$70 / optimista $80–$105. A $54, Dentro del rango de valor intrínseco razonable.

Al publicar $59.46 (24 de mayo de 2026)

Aún no hay análisis sobre este valor en tu idioma.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane for the treatment of breast cancer. Further, it provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; and NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. Bristol-Myers Squibb Company has a strategic collaboration with Arcus Biosciences, Inc. to develop a novel treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Capitalización112,89 mil MUS$
Ingresos (TTM)48,48 mil MUS$
EBITDA18,97 mil MUS$
Margen neto15,01 %
ROE38,73 %
PER (TTM)15,48
PER previsto8,87
PEG177,24
BPA3,57 US$
Rentabilidad por dividendo4,47 %
Rango de 52 semanas41,46 US$ – 62,25 US$
Precio objetivo de analistas63,08 US$
Recomendación de analistas3.5 / 5

Datos de EODHD, mostrados en la moneda de reporte; solo a título informativo, no constituye asesoramiento de inversión.

Historia

PróximamenteEsta sección se está completando; vuelve pronto.

Posición en el sector

PróximamenteEsta sección se está completando; vuelve pronto.